SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease.

Neurotherapeutics · 2021 · PMC8804111 · PMID 34738197

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The above effects of SPG302, along with our Golgi staining and behavioral data (highly significant at both doses), indicate that SPG302 induced the formation of new synapses.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.